ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study

被引：3
|
作者：
Moscetti, Luca [1 ,7 ]
Mentuccia, Lucia [2 ]
Vici, Patrizia [3 ]
Quadrini, Silvia [2 ]
Sperduti, Isabella [4 ]
Pizzuti, Laura [3 ]
Fabbri, Maria Agnese [1 ]
Vaccaro, Angela [2 ]
Sacca, Marcello Maugeri [3 ,6 ]
Barba, Maddalena [3 ,6 ]
Sergi, Domenico [3 ]
Zampa, Germano [5 ]
Gamucci, Teresa [2 ]
机构：
[1] Belcolle Hosp, AUSL Viterbo, Div Med Oncol, Viterbo, Italy
[2] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
[3] Regina Elena Inst Canc Res, Div Med Oncol B, Rome, Italy
[4] Regina Elena Inst Canc Res, Biostat, Rome, Italy
[5] Nuovo Regina Margherita Hosp, Med Oncol Unit, Rome, Italy
[6] Regina Elena Inst Canc Res, Sci Direct, Rome, Italy
[7] Azienda Osped Univ Policlin Modena, Dept Oncol & Hematol, Modena, Italy
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 17期
关键词：
Edmonton symptoms assessment scale; eribulin mesylate; metastatic breast cancer; quality of life; QUALITY-OF-LIFE; CAPECITABINE; MESYLATE; SCALE;
D O I：
10.2217/fon-2017-0062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations. Patients & methods: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires. Results: A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores. Conclusion: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.
引用
收藏
页码：1517 / 1525
页数：9
相关论文
共 50 条
  • [41] Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
    Junichiro Watanabe
    Yoshinori Ito
    Shozo Ohsumi
    Mitsuhiro Mizutani
    Hideya Tashiro
    Kenichi Sakurai
    Masato Takahashi
    Tsuyoshi Saito
    Junji Tsurutani
    Hirofumi Mukai
    Tetsuhiro Yoshinami
    Shintaro Takao
    Yasuhisa Yamamoto
    Toshiyuki Matsuoka
    Hirotaka Iwase
    Hiroji Iwata
    Seigo Nakamura
    Toshiaki Saeki
    [J]. Investigational New Drugs, 2017, 35 : 791 - 799
  • [42] Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
    Oruc, Zeynep
    Kaplan, Muhammet Ali
    Geredeli, Caglayan
    Sari, Nilgun Yildirim
    Ozaslan, Ersin
    Aytekin, Aydin
    Elkiran, Emin Tamer
    Koca, Sinan
    Dogan, Mutlu
    Turan, Nedim
    Yuce, Ozlem
    Sevinc, Alper
    Ercelep, Ozlem
    Isikdogan, Abdurrahman
    [J]. JOURNAL OF BUON, 2019, 24 (05): : 1876 - 1883
  • [43] Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
    Watanabe, Junichiro
    Ito, Yoshinori
    Ohsumi, Shozo
    Mizutani, Mitsuhiro
    Tashiro, Hideya
    Sakurai, Kenichi
    Takahashi, Masato
    Saito, Tsuyoshi
    Tsurutani, Junji
    Mukai, Hirofumi
    Yoshinami, Tetsuhiro
    Takao, Shintaro
    Yamamoto, Yasuhisa
    Matsuoka, Toshiyuki
    Iwase, Hirotaka
    Iwata, Hiroji
    Nakamura, Seigo
    Saeki, Toshiaki
    [J]. INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 791 - 799
  • [44] Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study
    Zhao, Yannan
    Xie, Ning
    Li, Wei
    Chen, Wenyan
    Lv, Zheng
    Zheng, Yabing
    Sun, Tao
    Liu, Jieqiong
    Zhang, Jian
    Hu, Shihui
    Wang, Yajun
    Gong, Chengcheng
    Li, Yi
    Xie, Yizhao
    Ge, Rui
    Xu, Fei
    Wang, Biyun
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [45] Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients: A Multicenter Prospective Observational Study
    Huang, Xinjuan
    Li, Xuying
    Li, Jinhua
    Luo, Lu
    Chen, Hongyun
    Tan, Yan
    Wei, Tao
    Li, Xingfeng
    Guo, Liwen
    Cheng, Jing
    [J]. ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2021, 8 (04) : 433 - 437
  • [46] Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin
    Bun, Ayako
    Nagahashi, Masayuki
    Kuroiwa, Mamiko
    Komatsu, Miki
    Miyoshi, Yasuo
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (03) : 575 - 583
  • [47] NEUTROPENIA MAY BE A PREDICTION MARKER OF THERAPEUTIC EFFECT IN METASTATIC BREAST CANCER PATIENTS TREATED WITH ERIBULIN
    Yoshimura, Yuri
    Kajiwara, Yukiko
    Kochi, Mariko
    Kono, Miho
    Ito, Mitsuya
    Ohtani, Shoichiro
    Higaki, Kenji
    [J]. BREAST, 2013, 22 : S47 - S47
  • [48] Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin
    Ayako Bun
    Masayuki Nagahashi
    Mamiko Kuroiwa
    Miki Komatsu
    Yasuo Miyoshi
    [J]. Breast Cancer Research and Treatment, 2023, 202 : 575 - 583
  • [49] Circulating TGFa and TNFa in metastatic breast cancer patients treated with eribulin. The TRANSERI project
    Garrone, Ornella
    Lo Nigro, Cristiana
    Michelotti, Andrea
    Montemurro, Fillippo
    Vandone, Anna Maria
    Abbona, Andrea
    Paccagnella, Matteo
    Falletta, Antonella
    Genua, Elena
    De Angelis, Claudia
    Tonissi, Federica
    Vanella, Paola
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [50] Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
    Chen, Pei-Hsin
    Yeh, Dah-Cherng
    Tung, Heng-Hsin
    Lin, Chin-Yao
    [J]. MEDICINE, 2021, 100 (47)
12345